Passion for Innovation. Compassion for Patients.™

Daiichi Sankyo Europe GmbH

Our Commitment to Cardiovascular Disease Treatment

“We strive to help patients with cardiovascular diseases by developing innovative treatments. Since 2002 our cardiovascular treatments have improved outcomes of over 40 million* patients across Europe.”

Cardiovascular medicines in our portfolio:

  • Adrenalin (an adrenal cortex hormone agent that became the first blockbuster cardiovascular medicine of the 20th century)
  • Pravastatin (a globally groundbreaking anti-hyperlipidemic agent)
  • Edoxaban (an anticoagulant and direct factor Xa inhibitor)

We are leaders in cardiovascular disease treatment. 

Our current portfolio contains treatments for cardiovascular diseases such as:

  • Atrial fibrillation
  • Thrombotic disorders
  • Hypertension
  • Hypercholestrolaemia

*40 million patients treated with olmesartan and its combinations, prasugrel, edoxaban, pravastatin in selected countries